CPT is working in partnership with Edison Pharma to bring forward EPI-743 into trial.  This drug which has been used to treat mitochondrial diseases in children has been selected by the Linked Clinical Trials committee as a high priority, as mitochondrial dysfunction is a feature of both genetic and non-genetic forms of Parkinson’s.  It is hoped that this trial will get underway later this year.

Click here to read more about this fascinating new area of research.